| abstract |
Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are 5 provided. These compositions of the present invention are found to specifically recognise the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided. Document53Dccument53 RSL* AR + vector 50. AR + 52 - AR mutant + vector R840 ARmutan+2 P721 100 260 30 40D 0 600 DHT (nM) |